Association of Insulin, Metformin, and Statin with Mortality in Breast Cancer Patients
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose This study investigated the association of insulin, metformin, and statin use with survival and whether the association was modified by the hormone receptor status of the tumor in patients with breast cancer. Materials and Methods We studied 7,452 patients who had undergone surgery for breast cancer at Seoul National University Hospital from 2008 to 2015 using the nationwide claims database. Exposure was defined as a recorded prescription of each drug within 12 months before the diagnosis of breast cancer. Results Patients with prior insulin or statin use were more likely to be older than 50 years at diagnosis and had a higher comorbidity index than those without it (p < 0.01 for both). The hazard ratio (HR) for death with insulin use was 5.7 (p < 0.01), and the effect was attenuated with both insulin and metformin exposure with an HR of 1.2 (p=0.60). In the subgroup analyses, a heightened risk of death with insulin was further prominent with an HR of 17.9 (p < 0.01) and was offset by co-administration of metformin with an HR of 1.3 (p=0.67) in patients with estrogen receptor (ER)–negative breast cancer. Statin use was associated with increased overall mortality only in patients with ER-positive breast cancer with HR for death of 1.5 (p=0.05). Conclusion Insulin or statin use before the diagnosis of breast cancer was associated with an increase in all-cause mortality. Subsequent analyses suggested that metformin or statin use may have been protective in patients with ER-negative disease, which warrants further studies.
Abstract
Purpose This study investigated the association of insulin, metformin, and statin use with survival and whether the association was modified by the hormone receptor status of the tumor in patients with breast cancer. Materials and Methods We studied 7,452 patients who had undergone surgery for breast cancer at Seoul National University Hospital from 2008 to 2015 using the nationwide claims database. Exposure was defined as a recorded prescription of each drug within 12 months before the diagnosis of breast cancer. Results Patients with prior insulin or statin use were more likely to be older than 50 years at diagnosis and had a higher comorbidity index than those without it (p < 0.01 for both). The hazard ratio (HR) for death with insulin use was 5.7 (p < 0.01), and the effect was attenuated with both insulin and metformin exposure with an HR of 1.2 (p=0.60). In the subgroup analyses, a heightened risk of death with insulin was further prominent with an HR of 17.9 (p < 0.01) and was offset by co-administration of metformin with an HR of 1.3 (p=0.67) in patients with estrogen receptor (ER)–negative breast cancer. Statin use was associated with increased overall mortality only in patients with ER-positive breast cancer with HR for death of 1.5 (p=0.05). Conclusion Insulin or statin use before the diagnosis of breast cancer was associated with an increase in all-cause mortality. Subsequent analyses suggested that metformin or statin use may have been protective in patients with ER-negative disease, which warrants further studies.
참고문헌 (31)
- Lee YH, "Health performance and challenges in Korea: a review of the global burden of disease study 2013", J Korean Med Sci, 31(Suppl 2), pp.S114~S120 (2016)
- GBD 2017 Causes of Death Collaborators, "Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017 : a systematic analysis for the Global Burden of Disease Study 2017", Lancet, 392, pp.1736~1788 (2018)
- Mehta LS, "Cardiovascular disease and breast cancer : where these entities intersect : a scientific statement from the American Heart Association", Circulation, 137, pp.e30~66 (2018)
- Tang GH, "Association of metformin with breast cancer incidence and mortality in patients with type II diabetes : a GRADE-assessed systematic review and meta-analysis", Cancer Epidemiol Biomarkers Prev, 27, pp.627~635 (2018)
- Beckwitt CH, "Statin drugs to reduce breast cancer recurrence and mortality", Breast Cancer Res, 20, pp.144~ (2018)
- Chen L, "Diabetes treatments and risks of adverse breast cancer outcomes among early-stage breast cancer patients : a SEERmedicare analysis", Cancer Res, 77, pp.6033~6041 (2017)
- Borgquist S, "Cholesterol, cholesterol-lowering medication use, and breast cancer outcome in the BIG 1-98 study", J Clin Oncol, 35, pp.1179~1188 (2017)
- Sonnenblick A, "Impact of diabetes, insulin, and metformin use on the outcome of patients with human epidermal growth factor receptor 2-positive primary breast cancer : analysis from the ALTTO phase III randomized trial", J Clin Oncol, 35, pp.1421~1429 (2017)
- Jackson JW, "Studying the effects of nonindicated medications on cancer : etiologic versus action-focused analysis of epidemiologic data", Cancer Epidemiol Biomarkers Prev, 27, pp.520~524 (2018)
- Liu B, "The relationship between statins and breast cancer prognosis varies by statin type and exposure time : a meta-analysis", Breast Cancer Res Treat, 164, pp.1~11 (2017)
- Bhoo-Pathy N, "Breast cancer research in Asia: adopt or adapt Western knowledge?", Eur J Cancer, 49, pp.703~709 (2013)
- Kim DS, "Introduction : health of the health care system in Korea", Soc Work Public Health, 25, pp.127~141 (2010)
- 김지애, "Towards Actualizing the Value Potential of Korea Health Insurance Review and Assessment (HIRA) Data as a Resource for Health Research: Strengths, Limitations, Applications, and Strategies for Optimal Use of HIRA Data", Journal of Korean Medical Science, 32(5), pp.718~728 (2017), 대한의학회
- Charlson ME, "A new method of classifying prognostic comorbidity in longitudinal studies : development and validation", J Chronic Dis, 40, pp.373~383 (1987)
- Quan H, "Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data", Med Care, 43, pp.1130~1139 (2005)
- Greene FL, "AJCC cancer staging manual" (2002), Springer
- Edge SB, "AJCC cancer staging manual" (2010), Springer
- Gernaat SAM, "Risk of death from cardiovascular disease following breast cancer : a systematic review", Breast Cancer Res Treat, 164, pp.537~555 (2017)
- Abdel-Qadir H, "A population-based study of cardiovascular mortality following early-stage breast cancer", JAMA Cardiol, 2, pp.88~93 (2017)
- Hershman DL, "Association of cardiovascular risk factors with cardiac events and survival outcomes among patients with breast cancer enrolled in SWOG clinical trials", J Clin Oncol, 36, pp.2710~2717 (2018)
- American Diabetes Association, "8. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2018", Diabetes Care, 41(Suppl 1), pp.S73~S85 (2018)
- Chou R, "Statins for prevention of cardiovascular disease in adults : evidence report and systematic review for the US Preventive Services Task Force", JAMA, 316, pp.2008~2024 (2016)
- Duggan C, "Associations of insulin resistance and adiponectin with mortality in women with breast cancer", J Clin Oncol, 29, pp.32~39 (2011)
- Chappell J, "Effect of insulin on cell cycle progression in MCF-7 breast cancer cells. Direct and potentiating influence", J Biol Chem, 276, pp.38023~38028 (2001)
- Calle EE, "Overweight, obesity and cancer : epidemiological evidence and proposed mechanisms", Nat Rev Cancer, 4, pp.579~591 (2004)
- Dowling RJ, "Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells", Cancer Res, 67, pp.10804~10812 (2007)
- Goodwin PJ, "Effect of metformin vs placebo on and metabolic factors in NCIC CTG MA.32", J Natl Cancer Inst, 107, pp.djv006~ (2015)
- Liu B, "Metformin induces unique biological and molecular responses in triple negative breast cancer cells", Cell Cycle, 8, pp.2031~2040 (2009)
- Goard CA, "Identifying molecular features that distinguish fluvastatin-sensitive breast tumor cells", Breast Cancer Res Treat, 143, pp.301~312 (2014)
- Campbell MJ, "Breast cancer growth prevention by statins", Cancer Res, 66, pp.8707~8714 (2006)
- Goodwin PJ, "Insulin-and obesity-related variables in earlystage breast cancer : correlations and time course of prognostic associations", J Clin Oncol, 30, pp.164~171 (2012)